Latest News

Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.

Phase 2 Study of Nivolumab Plus Ipilimumab for Gastric, Ovarian, and Breast Cancer

Phase 2 Study of Nivolumab Plus Ipilimumab for Gastric, Ovarian, and Breast Cancer

For this open-label phase 2 study, researchers are evaluating the safety and efficacy of nivolumab and ipilimumab among patients with 1 of these 3 cancer types.

Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

Phase 1 Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

Researchers are evaluating the feasibility and safety of adjuvant HIPEC in patients with locally advanced gastric cancer.

Chemotherapy Followed by Radiotherapy Improves Survival in Negative-margin NSCLC

Chemotherapy Followed by Radiotherapy Improves Survival in Negative-margin NSCLC

Data from previous studies suggest that adjuvant chemotherapy and PORT may improve patient outcomes, but the optimal sequence of administration was previously unestablished.

Phase 1 Study of A Virus-based Gene Therapy for Non-small Cell Lung Cancer

Phase 1 Study of A Virus-based Gene Therapy for Non-small Cell Lung Cancer

Researchers are evaluating whether Ad5-yCD/mutTKSR39rep-ADP, an oncolytic adenovirus, can help to improve outcomes among patients with inoperable stage I/IIA NSCLC.

Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer

Non-steroidal Anti-inflammatory Drugs May Improve Survival in Kidney Cancer

A cumulative-use analysis suggests that NSAIDs, ACEis, and SSRIs improve disease-specific outcomes among patients with kidney cancer, and further that NSAIDs improve overall survival.

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

Caplacizumab: A New Treatment Option for Acquired Thrombotic Thrombocytopenic Purpura

The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Oral Edoxaban Non-inferior to Dalteparin for Cancer-associated Venous Thromboembolism

Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.

4R + 3Dex May Improve Outcomes in Pediatric Chronic ITP

4R + 3Dex May Improve Outcomes in Pediatric Chronic ITP

Young patients with chronic ITP may experience relapse within 5 years of completing therapy.

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Elderly Patients Underrepresented in Studies Evaluating Hematologic Malignancies

Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.

PET-CT Alone May Not Distinguish Richter Transformation in CLL

PET-CT Alone May Not Distinguish Richter Transformation in CLL

Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.

Axillary Node Management for Breast Cancer: Is Less More?

Axillary Node Management for Breast Cancer: Is Less More?

Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

Carfilzomib, Lenalidomide, Dexamethasone Prolong Survival in Multiple Myeloma

The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

Bortezomib-based Induction Improves PFS, OS in High-risk Newly Diagnosed Multiple Myeloma

A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma

Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma

Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer

This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.

CTS5 Predicts Late Distant Recurrence in Hormone Receptor-positive Breast Cancer

CTS5 Predicts Late Distant Recurrence in Hormone Receptor-positive Breast Cancer

The CTS5 model is based on nodal status, tumor size, 3 categories of tumor grade, and age as a continuous variable.

Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma

Minimum Residual Disease: A Surrogate Marker for Assessing Outcomes in Multiple Myeloma

Patients who presented with an MRD level below 10-6 had a significantly improved PFS compared with patients who were above this threshold.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters